RVMDW (Revolution Medicines, Inc. Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by RVMDW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Stephen Michael Kelsey | See Remarks | Sell | — | — |
| 2026-06-18 | Jeff Cislini | General Counsel | Sell | — | — |
| 2026-06-18 | MARK A GOLDSMITH | See Remarks | Sell | — | — |
| 2026-06-18 | Jack Anders | Chief Financial Officer | Sell | — | — |
| 2026-06-18 | Anthony Mancini | See Remarks | Sell | — | — |
| 2026-06-17 | Margaret A Horn | Chief Operating Officer | MIXED | — | — |
| 2026-06-15 | Margaret A Horn | Chief Operating Officer | MIXED | — | — |
| 2026-05-28 | Anthony Mancini | See Remarks | MIXED | — | — |
| 2026-04-29 | Anthony Mancini | See Remarks | MIXED | — | — |
| 2026-04-17 | MARK A GOLDSMITH | See Remarks | MIXED | — | — |
| 2026-03-26 | Anthony Mancini | See Remarks | MIXED | — | — |
| 2026-03-19 | Xiaolin Wang | See Remarks | Sell | — | — |
| 2026-03-19 | Jeff Cislini | General Counsel | Sell | — | — |
| 2026-03-19 | Jack Anders | Chief Financial Officer | Sell | — | — |
| 2026-03-19 | Margaret A Horn | Chief Operating Officer | Sell | — | — |
| 2026-03-19 | MARK A GOLDSMITH | See Remarks | Sell | — | — |
| 2026-03-19 | Stephen Michael Kelsey | See Remarks | Sell | — | — |
| 2026-03-19 | Lin Wei | Chief Medical Officer | Sell | — | — |
| 2026-03-06 | ELIZABETH M ANDERSON | Director | G | — | — |
| 2026-03-03 | Jack Anders | Chief Financial Officer | A | — | — |
| 2026-03-03 | Jeff Cislini | General Counsel | A | — | — |
| 2026-03-03 | Margaret A Horn | Chief Operating Officer | A | — | — |
| 2026-03-03 | MARK A GOLDSMITH | See Remarks | MIXED | — | — |
| 2026-03-03 | Stephen Michael Kelsey | See Remarks | A | — | — |
| 2026-03-03 | Lin Wei | Chief Medical Officer | A | — | — |
| 2026-03-03 | Xiaolin Wang | See Remarks | A | — | — |
| 2026-02-10 | MARK A GOLDSMITH | See Remarks | M | — | — |
| 2026-01-23 | Jeff Cislini | General Counsel | Sell | — | — |
| 2026-01-09 | Jack Anders | Chief Financial Officer | MIXED | — | — |
| 2026-01-09 | Margaret A Horn | Chief Operating Officer | MIXED | — | — |
| 2025-12-18 | Jack Anders | Chief Financial Officer | Sell | — | — |
| 2025-12-18 | Margaret A Horn | Chief Operating Officer | Sell | — | — |
| 2025-12-18 | Stephen Michael Kelsey | See Remarks | Sell | — | — |
| 2025-12-18 | MARK A GOLDSMITH | See Remarks | Sell | — | — |
| 2025-12-18 | Jeff Cislini | General Counsel | Sell | — | — |
| 2025-11-26 | MARK A GOLDSMITH | See Remarks | MIXED | — | — |
| 2025-11-26 | Jack Anders | Chief Financial Officer | MIXED | — | — |
| 2025-11-20 | Jeff Cislini | General Counsel | MIXED | — | — |
| 2025-11-20 | MARK A GOLDSMITH | See Remarks | MIXED | — | — |
| 2025-11-14 | MARK A GOLDSMITH | See Remarks | MIXED | — | — |
| 2025-11-13 | Jack Anders | Chief Financial Officer | MIXED | — | — |
| 2025-11-12 | MARK A GOLDSMITH | See Remarks | MIXED | — | — |
| 2025-10-20 | MARK A GOLDSMITH | See Remarks | MIXED | — | — |
| 2025-10-20 | Jeff Cislini | General Counsel | MIXED | — | — |
| 2025-10-15 | Stephen Michael Kelsey | See Remarks | MIXED | — | — |
| 2025-09-26 | Jeff Cislini | General Counsel | Sell | — | — |
| 2025-09-18 | Jack Anders | Chief Financial Officer | Sell | — | — |
| 2025-09-18 | Jeff Cislini | General Counsel | Sell | — | — |
| 2025-09-18 | Margaret A Horn | Chief Operating Officer | Sell | — | — |
| 2025-09-18 | MARK A GOLDSMITH | See Remarks | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,338,884 | — |
| — | Director | 760,869 | — |
| — | See Remarks | 331,754 | — |
| — | See Remarks | 291,876 | — |
| — | Chief Operating Officer | 218,622 | — |
| — | Chief Financial Officer | 123,269 | — |
| — | See Remarks | 116,063 | — |
| — | Chief Medical Officer | 101,366 | — |
| — | Director | 96,574 | — |
| — | Director | 73,090 | — |
| — | General Counsel | 56,521 | — |
| — | See Remarks | 49,975 | — |
| — | Director | 35,205 | — |
| — | Director | 25,024 | — |
| — | Director | 23,090 | — |
| — | Director | 13,065 | — |
| — | Director | 9,738 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RVMDW quote page; the site-wide leaderboard is on the insider transactions hub.